The NFIL3 transcription factor is preferentially expressed in BCR-independent mature B-cell malignancy

The NFIL3 transcription factor is preferentially expressed in BCR-independent mature B-cell malignancy

Detalhes bibliográficos
Principais autores:	Gascoyne, D, Lyne, L, Spearman, H, Soilleux, E, Banham, A
Formato:	Conference item
Publicado em:	2012

Registros relacionados

Vitamin D receptor expression in plasmablastic lymphoma and myeloma cells confers susceptibility to vitamin D
por: Gascoyne, D, et al.
Publicado em: (2016)

FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas
por: Brown, P, et al.
Publicado em: (2015)

The transcription factor NFIL3 controls regulatory T-cell function and stability
por: Hyeong Su Kim, et al.
Publicado em: (2019-07-01)

FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures
por: Wong, K, et al.
Publicado em: (2016)

Diurnal Rhythmicity Programs of Microbiota and Transcriptional Oscillation of Circadian Regulator, NFIL3
por: Masato Kubo, et al.
Publicado em: (2020-09-01)

N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.
por: Brown, P, et al.
Publicado em: (2016)

The forkhead transcription factor FOXP2 is required for regulation of p21WAF1/CIP1 in 143B osteosarcoma cell growth arrest
por: Gascoyne, DM, et al.
Publicado em: (2015)

NFIL3 contributes to cytotoxic T lymphocyte-mediated killing
por: Tiphaine Douanne, et al.
Publicado em: (2024-02-01)

Genetic Deletion of the Transcriptional Repressor NFIL3 Enhances Axon Growth In Vitro but Not Axonal Repair In Vivo.
por: Loek R van der Kallen, et al.
Publicado em: (2015-01-01)

The Forkhead Transcription Factor FOXP2 Is Required for Regulation of p21WAF1/CIP1 in 143B Osteosarcoma Cell Growth Arrest.
por: Duncan M Gascoyne, et al.
Publicado em: (2015-01-01)

NFIL3 and its immunoregulatory role in rheumatoid arthritis patients
por: Juping Du, et al.
Publicado em: (2022-11-01)

N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells
por: Philip J. Brown, et al.
Publicado em: (2016-07-01)

The basic leucine zipper transcription factor NFIL3 directs the development of a common innate lymphoid cell precursor
por: Xiaofei Yu, et al.
Publicado em: (2014-10-01)

NFIL3 aggravates human coronary artery endothelial cell injury by promoting ITGAM transcription in Kawasaki disease
por: Li Chen, et al.
Publicado em: (2023-12-01)

A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies
por: Liggins, A, et al.
Publicado em: (2010)

A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies.
por: Liggins, A, et al.
Publicado em: (2010)

NFIL3 Orchestrates the Emergence of Common Helper Innate Lymphoid Cell Precursors
por: Wei Xu, et al.
Publicado em: (2015-03-01)

Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients
por: Wong, K, et al.
Publicado em: (2014)

Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.
por: Wong, K, et al.
Publicado em: (2014)

dJun and Vri/dNFIL3 are major regulators of cardiac aging in Drosophila.
por: Véronique Monnier, et al.
Publicado em: (2012-01-01)

NFIL3 deficiency alleviates EAE through regulating different immune cell subsets
por: Zhigang Chen, et al.
Publicado em: (2022-07-01)

NFIL3/Tim3 axis regulates effector Th1 inflammation in COPD mice
por: Junyi Ke, et al.
Publicado em: (2024-11-01)

The significance of FOXP1 in diffuse large B-cell lymphoma
por: Gascoyne, D, et al.
Publicado em: (2016)

Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.
por: Banham, A, et al.
Publicado em: (2005)

The BCL11AXL transcription factor: its distribution in normal and malignant tissues and use as a marker for plasmacytoid dendritic cells.
por: Pulford, K, et al.
Publicado em: (2006)

Expression of NFIL3 and CEBPA regulated by IFNT induced-PGE2 in bovine endometrial stromal cells during the pre-implantation period
por: Rulan Bai, et al.
Publicado em: (2023-02-01)

Ferroptosis and inflammation are modulated by the NFIL3-ACSL4 axis in sepsis associated-acute kidney injury
por: Zhong Xiao, et al.
Publicado em: (2024-08-01)

Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies
por: Laura Ondrisova, et al.
Publicado em: (2020-10-01)

Role of the tumor microenvironment in mature B-cell lymphoid malignancies
por: Nathan H. Fowler, et al.
Publicado em: (2016-05-01)

Higher incidence of co-expression of BCR-ABL fusion transcripts in an Eastern Indian population
por: Ajeet Kumar, et al.
Publicado em: (2023-10-01)

Expression of FOXP2 is up-regulated in lymphoid malignancies
por: Campbell, A, et al.
Publicado em: (2009)

CD40 signaling synergizes with TLR-2 in the BCR independent activation of resting B cells.
por: Shweta Jain, et al.
Publicado em: (2011-01-01)

Preferential transcription of Paracoccidioides brasiliensis genes: host niche and time-dependent expression
por: Maristela Pereira, et al.
Publicado em: (2009-05-01)

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
por: Federica Loscocco, et al.
Publicado em: (2019-09-01)

A <it>Myc</it>-regulated transcriptional network controls B-cell fate in response to BCR triggering
por: Vaigot Pierre, et al.
Publicado em: (2009-07-01)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Dachuan Zeng, et al.
Publicado em: (2022-05-01)

Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio
por: Ilaria Iacobucci, et al.
Publicado em: (2007-03-01)

Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities
por: Peter Valent
Publicado em: (2011-10-01)

Aberrant expression of the neuronal transcription factor FOXP2 in neoplastic plasma cells.
por: Campbell, A, et al.
Publicado em: (2010)

Editorial: BCR Signaling and B Cell Activation
por: Wanli Liu, et al.
Publicado em: (2020-01-01)